Neuroscience · Skim version

When Mature Neurons Fail: Neurodegeneration

About 2 min to skim · 2 figures · Rewritten on

Read the full lesson → Skim the whole course →

The guiding idea

Lecanemab slowed worsening in early Alzheimer disease by about 27%. The treated group still got worse.

Each kind of evidence about neurodegeneration supports some claims and not others: an autopsy shows what builds up, families show what can start the disease, and randomized trials test whether changing it helps.

From the film: Three Questions, Three Kinds of Evidence

  • Each kind of evidence supports some claims and not others.
  • An autopsy shows what builds up, and families can show what can start the disease.
  • Randomized trials in people give the most direct test of whether changing a target helps.

From the film: Slower Worsening Is Still Worsening

  • In the lecanemab trial both groups got worse, and the gap was a little more than a quarter of the placebo decline.
  • That share compares two amounts of decline, and slower worsening is still worsening.
  • A change in a biomarker is not a clinical benefit, and benefits can come with costs such as brain swelling on MRI.

From the film: Protecting Cut Axons Did Not Rescue This ALS Model

  • Removing Sarm1 protects cut axons, but in mice that make mutant human SOD1 it did not improve the disease measures.
  • Needed after a cut does not mean needed in the disease, and one mouse model is not human ALS.
  • The result does not show that axon loss is unimportant in ALS, so the next test should measure more outcomes and be repeated in a second model.
  1. Four questions and one idea

  2. Which neurons die: three diseases, three populations

    AI-generated illustration: A medial view of the brain and upper spinal cord with gold marking the neurons lost: entorhinal cortex and hippocampal CA1 early in Alzheimer disease, substantia nigra dopamine neurons in Parkinson disease, and motor cortex upper motor neurons with their descending axons in ALS. An inset of the spinal cord marks the ventral-horn lower motor neurons also lost in ALS.
    Each disease strikes particular neurons and spares others: entorhinal and CA1 neurons early in Alzheimer disease, nigral dopamine neurons in Parkinson disease, and upper and lower motor neurons in ALS. AI-generated illustration
  3. What builds up: proteins that clump

    AI-generated illustration: Three neurons compared: in Alzheimer disease an amyloid plaque lies outside the cell and a tau tangle inside; in Parkinson disease a Lewy body made of alpha-synuclein filaments sits in the cell body and a Lewy neurite in a process; in ALS, TDP-43 has left the nucleus and gathered in a cytoplasmic inclusion.
    Each disease has its own deposit at autopsy: amyloid plaques outside and tau tangles inside neurons in Alzheimer disease, alpha-synuclein Lewy bodies and neurites in Parkinson disease, and TDP-43 that has left the nucleus for a cytoplasmic inclusion in most ALS. AI-generated illustration
  4. What can start it: genes that cause and genes that raise risk

  5. Does removing it help: testing amyloid in trials

  6. Why these neurons

  7. Going deeper

Read the full lesson → Skim the whole course →